Catalent seeks slice of gene therapy market with Paragon buy


By Saumya Joseph

(Reuters) - Contract drugmaker Catalent Inc said on Monday it would buy privately held Paragon Bioservices Inc for $1.2 billion in cash, bolstering its capabilities to make gene therapy drugs for its biotech clients.

Paragon, backed by private-equity firms Camden Partners and NewSpring Capital, focuses on developing and making complex biopharmaceuticals for its clients and is expected to bring in more than $200 million in revenue this year, Catalent said.

"Paragon's unparalleled expertise in the rapidly growing market of gene therapy manufacturing will be a transformative addition to our business that we believe will accelerate our long-term growth," Catalent Chief Executive Officer John Chiminski said in a statement.

Most emerging drug companies lack the resources to manufacture drugs and rely on contract organizations such as Catalent and Paragon to make the drugs using their technology.

"Over the next 3 to 5 years, demand is going to far outstrip capacity. Customers are really looking to lock up as much manufacturing capacity as they can," Chiminski said on a conference call with analysts.

The deal comes less than a month after Thermo Fisher Scientific Inc signed a $1.7 billion deal to buy gene therapy contract manufacturer Brammer Bio.

Evercore ISI analyst Ross Muken said the M&A activity is likely to continue and expects contract manufacturers to expand their gene therapy capabilities due to the potential of these treatments to drive the next major leg of industry growth.

Catalent said it expects the transaction to add to its adjusted earnings in the second full fiscal year after closing, which is expected in the second quarter of 2019.

The company intends to fund the deal with proceeds from a $650 million incremental term loan and issuance of $650 million of a new series of convertible preferred stock.

Catalent has inked a number of deals over the years, including last year's purchase of drug developer Juniper Pharmaceuticals Inc and a $950 million buyout of Cook Pharmica LLC in 2017.

Separately, Paragon said it will look to expand its partnership with gene therapy maker Sarepta Therapeutics Inc by establishing additional manufacturing facilities.

Related Articles

FEATURE-Only for 'naughty girls': stigma lingers after S. Korea abortion ban overturned

By Beh Lih Yi KUALA LUMPUR (Thomson Reuters Foundation) - South Korea is set to legalize abortion after a decades-long ban was struck down, but women's rights campaigners have warned those who undergo Read More »

Tailored program might help some with severe mental illness quit smoking

By Anne Harding NEW YORK (Reuters Health) - A smoking-cessation program tailored to people with schizophrenia and bipolar disorder may help some quit, new findings show. "It doesn't disrupt their Read More »

IBD patients who switch from infliximab to biosimilar see mixed results

By Will Boggs MD NEW YORK (Reuters Health) - Patients with inflammatory bowel disease (IBD) can safely switch from infliximab to the biosimilar CT-P13, though they may face a higher risk of clinical Read More »